Virtual
FOURTH CONGRESS
of the
Italian Society
for Virology

WEBINAR
FRIDAY, DECEMBER 11th, 2020
from 10.00 a.m. to 4.30 p.m.
RATIONAL

The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS CoV-2 virus and the COVID 19 disease were unknown before the outbreak began in Wuhan, China, in December 2019. The outbreak rapidly evolved, affecting other parts of China and other countries worldwide. On 30 January 2020, WHO declared that the outbreak of coronavirus disease (COVID-19) constituted a Public Health Emergency of International Concern and 11 March 2020, the Director General of WHO declared the COVID-19 outbreak a pandemic. The long incubation period of this new virus, which is mostly asymptomatic yet contagious, is a key reason for its rapid spread across the world.

Currently, there is no worldwide-approved treatment for COVID-19. Therefore, the clinical and scientific communities have joint efforts to reduce the severe impact of the outbreak. Research on previous emerging infectious diseases have created valuable knowledge that is being exploited for drug repurposing and accelerated vaccine development. However, it is important to generate knowledge on SARS-CoV-2 mechanisms of infection and its impact on host immunity, to guide the design of COVID-19 specific therapeutics and vaccines suitable for mass immunization.

The SARS-CoV-2 is a new strain of coronavirus, and the scientific community is rapidly gaining tremendous knowledge about this virus. Understanding of individual and population-level immunity to SARS-CoV-2 remains incomplete and developing reliable serological assays to detect previous infection has been an intense focus of the global scientific effort. Prevention of SARS-CoV-2 new infections may be the most effective approach, not only to prevent COVID-19 but also to block the spreading of the virus worldwide. Since the end of 2019, large efforts on multiple strategies are being adopted for the SARS-CoV-2 vaccine development. The development of a COVID-19 vaccine suitable for mass immunization is urgent and companies and research institutes have already reported the development of more than 115 vaccine candidates. Reorientation of research at many academic and industrial institutions is also currently in place, taking advantage of already existing knowledge and experience in fighting previous infectious diseases that may bring new solutions to the COVID-19 pipeline.

Thus, the large amount of information generated and reported in the last months raises the need for a consensus analysis, which is the rationale of this meeting.
SCIENTIFIC COMMITTEE

Guido Antonelli
Full Professor of Microbiology and Clinical Microbiology,
Department of Molecular Medicine,
"Sapienza" University of Rome, Italy

Arnaldo Caruso
Full Professor of Microbiology and Virology,
University of Brescia Medical School,
Brescia, Italy

Massimo Clementi
Full Professor of Microbiology and Virology,
"Vita-Salute" San Raffaele University,
Milan, Italy

FACULTY

GUIDO ANTONELLI (Rome, Italy)
CANIO BUONAVOGLIA (Bari, Italy)
FRANCESCA CACCURI (Brescia, Italy)
MARIA ROSARIA CAPOBIANCHI (Rome, Italy)
ARNALDO CARUSO (Brescia, Italy)
FRANCESCO CASTELLI (Brescia, Italy)
ROBERTA CAVALLO (Turin, Italy)
MASSIMO CLEMENTI (Milan, Italy)
MASSIMILIANO GALDIERO (Napoli, Italy)
GIUSEPPE IPPOLITO (Rome, Italy)
GIORGIO PALÙ (Padua, Italy)
MAURO PISTELLO (Pisa, Italy)
GUIDO POLI (Milan, Italy)
GIUSEPPE PORTELLA (Napoli, Italy)
ROBERTA Rizzie (Ferrara, Italy)
GUIDO SILVESTRI (Atlanta, USA)
OMBRETTA TURRIZIANI (Rome, Italy)
DAVIDE ZELLA (Baltimore, USA)
### 1st SESSION - Morning

**Chairmen:** G. Antonelli (Rome, Italy), A. Caruso (Brescia, Italy), G. Portella (Napoli, Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00-10.10</td>
<td>Introduction</td>
</tr>
<tr>
<td>A. Caruso</td>
<td>(Brescia, Italy)</td>
</tr>
<tr>
<td>10.10-10.30</td>
<td>Animal coronaviruses</td>
</tr>
<tr>
<td>C. Buonavoglia</td>
<td>(Bari, Italy)</td>
</tr>
<tr>
<td>10.30-10.50</td>
<td>Origin and evolution of SARS-CoV-2</td>
</tr>
<tr>
<td>G. Palù</td>
<td>(Padua, Italy)</td>
</tr>
<tr>
<td>10.50-11.10</td>
<td>SARS-CoV-2 pandemic: how the virus spread around the world</td>
</tr>
<tr>
<td>G. Ippolito</td>
<td>(Rome, Italy)</td>
</tr>
<tr>
<td>11.10-11.30</td>
<td>Molecular correlates of SARS-CoV-2 infection</td>
</tr>
<tr>
<td>M. Clementi</td>
<td>(Milan, Italy)</td>
</tr>
<tr>
<td>11.30-11.50</td>
<td>SARS-CoV-2 mutations and possible implications for pathogenesis</td>
</tr>
<tr>
<td>D. Zella</td>
<td>(Baltimore, USA)</td>
</tr>
<tr>
<td>11.50-12.30</td>
<td>Discussion</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td>Break</td>
</tr>
</tbody>
</table>
DECEMBER, 11th · Scientific Program · Afternoon

2nd SESSION - Afternoon
Chairmen: R. Cavallo (Turin, Italy), M. Galdiero (Napoli, Italy), M. Pistello (Pisa, Italy)

13.30-13.50 Evolving testing strategy in view of new tools and increased opportunities
M.R. Capobianchi (Rome, Italy)

13.50-14.10 Endothelial cell dysfunction: a major player in SARS-CoV-2 infection
F. Caccuri (Brescia, Italy)

14.10-14.30 COVID-19: a clue from innate immunity
R. Rizzo (Ferrara, Italy)

14.30-14.50 How the body reacts to SARS-CoV-2?
G. Poli (Milan, Italy)

14.50-15.10 The light and shadow of a vaccine against SARS-CoV-2
G. Silvestri (Atlanta, USA)

15.10-15.30 Antiviral therapy: updates and hopes
O. Turriziani (Rome, Italy)

15.30-15.50 Clinical management of patients with COVID-19
F. Castelli (Brescia, Italy)

15.50-16.20 Discussion

16.20-16.30 Conclusions
G. Antonelli (Rome, Italy), A. Caruso (Brescia, Italy), M. Clementi (Milan, Italy)
GENERAL INFORMATIONS

DATE
FRIDAY, DECEMBER 11TH , 2020
From 10.00 a.m. to 4.30 p.m.

CONGRESS VENUE
Webinar Congress
https://bit.ly/3kQ3Vgn

OFFICIAL LANGUAGE
Italian

ORGANIZING SECRETARIAT AND PROVIDER NR. 265

Nadirex International S.r.l.
Via Riviera, 39 - 27100 Pavia
Tel. +39.0382.525714 - Fax. +39.0382.525736
gloria.molla@nadirex.com
www.nadirex.com
Id ECM: 265-308306

- **Learning hours**: 6
- **Educational goal**: 32 - Special subjects of the National and/or Regional Health Service defined as urgent and/or extraordinary by the National Commission for continuous education and by autonomous regions/provinces for purposes of managing specific health emergencies, with acquisition of technical knowledge.
- **Special subject**: Coronavirus 2019-nCov infection
- **CME credits**: Nr. 10,8
- **Participants**: 300
- **RL (Remote Learning) product type**: Live courses on dedicated multimedia platform (Virtual Classroom, Webinar) - Synchronous RL

**PARTICIPANT RESOURCES REQUIRED**

Email address (for registration), recent and updated web browser, Internet connection, devices to enable use of learning contents (pc, smartphone or tablet) with speakers (or earphones), microphone (only if the course calls for verbal interaction between teachers and participants).
ADDRESSES OF THE CONGRESS
The Congress is addressed to the following figures:
• Physician (Disciplines: all disciplines)
• Biologist
• Pharmacist (Disciplines: Hospital Pharmacy, Local Pharmacy)
• Psychologist (Disciplines: Psychology, Psychotherapy)
• Chemist
• Biomedical Laboratory Technician
• Nurse

LEARNING VERIFICATION METHOD
Online multiple-choice questionnaire with double randomization. To earn ECM credits for the event you must:
• attend 90% of the teaching activities
• give correct answers to at least 75% of the questions on the questionnaire (a maximum of five attempts to pass the test are allowed, subject to repetition of content activities for each attempt);
• fill out the RL evaluation form and the quality and learning needs questionnaire
Attention: the questionnaire will be online for only 3 (three) days after the event has concluded.

Nadirex International assumes all responsibility for the contents, quality, and ethical correctness of this ECM activity.

For further informations please contact the Organizing Secretariat:
gloria.molla@nadirx.com - tel +39 0382 525736
WITH THE UNRESTRICTED EDUCATIONAL GRANTS OF: